Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628841 | 0.80 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL9097481 | 0.78 | MAPK1 (0.30) | MAPK1 | |
| SCHEMBL26622131 | 0.77 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL15888456 | 0.76 | MAPK1 (0.37) | MAPK1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL79874 | 0.76 | MAPK1 (0.37) | MAPK1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL704188 | 0.74 | MAPK1 (0.36) | MAPK1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL18924906 | 0.72 | ALDH1A1 (0.41) | MAPK1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL19720997 | 0.72 | MAPK1 (0.34) | MAPK1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL7403172 | 0.72 | ESR1 (0.35) | — | |
| SCHEMBL707572 | 0.72 | MAPK1 (0.34) | MAPK1SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567354-B2 | Amino acid-modified silane compounds and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| EP-2687529-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| US-9029388-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8846713-B2 | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| EP-2687529-A1 | CONDENSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20130331409-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-12 | — | — | US | disclosed |
| US-20130303553-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| EP-2585462-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-20120209020-A1 | AMINO ACID-MODIFIED SILANE COMPOUNDS AND MAKING METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| WO-2011163355-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | WO | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-5348890-A | In an aqueous solvent | NOF CORPORATION (JP) | 1994-09-20 | — | — | US | disclosed |
| EP-0545367-A1 | Trioxane derivatives, process for the preparation thereof, and method for the chemiluminescence | NOF CORPORATION (JP) | 1993-06-09 | — | — | EP | disclosed |
| US-4675317-A | PENICILLIN ANTIBIOTICS | MERCK & CO., INC. (US) | 1987-06-23 | — | — | US | disclosed |
| EP-0115308-A2 | 2-Unsaturated alkylthio-pen-2-em-3-carboxylic acids and process for preparing substituted 2-thioxopenams and 2-substituted thiopenems | MERCK & CO. INC. (US) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | MAPK1 1560/4885SMYD2 1384/4885CYP3A4 757/4885 |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE5A, PDE2A, PDE3A | MAPK1 1588/4885SMYD2 731/4885CYP3A4 463/4885 |
| US-20130303553-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE5A, PDE2A, PDE3A | MAPK1 1588/4885SMYD2 731/4885CYP3A4 463/4885 |
| US-20130331409-A1 | CONDENSED HETEROCYCLIC COMPOUND | PDE10A, PDE5A, PDE3B | MAPK1 504/4885SMYD2 954/4885CYP3A4 2338/4885 |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | MAPK1 1560/4885SMYD2 1384/4885CYP3A4 757/4885 |
| US-20120209020-A1 | AMINO ACID-MODIFIED SILANE COMPOUNDS AND MAKING METHOD | BCAT2, BCAT1, ASNS | MAPK1 1575/4885SMYD2 346/4885CYP3A4 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.